DSGX Descartes Systems Group Inc

$DSGX currently listed as a top long opportunity on the Top Tier Newswire AI model! $TLX is another notable entry with their FDA approval of Telix’s brain cancer imaging drug Pixclara.

Descartes Systems reported a strong fiscal Q2 2027 performance, with results significantly exceeding analyst expectations. Revenue reached a record $201.1 million, up 12% year over year and above consensus of about $199.4 million, while diluted EPS rose 33% to $0.57, beating estimates of $0.55. Adjusted EBITDA also hit a record $94.4 million, with the margin expanding to an all-time high of 47%, while net income increased 32% to $50 million. Analyst sentiment strengthened following the results, with Scotiabank raising its price target after organic service revenue growth came in above expectations at just over 9%. Demand was particularly strong for Global Trade Intelligence, e-commerce customs filing and fleet performance solutions. Descartes also continues to pursue an active acquisition strategy, completing the $120 million Extensiv acquisition and buying Tai for approximately $100 million after quarter-end. $DSGX